47,200€
-0,84%
Echtzeit-Aktienkurs LivaNova PLC
Bid:
Ask:
Echtzeit-Chart der LivaNova PLC Aktie
Börsenkurse LivaNova PLC
| gettex | - | - | - | - | 47,200€ | -0,84% |
| Börse Stuttgart | - | - | - | - | 46,200€ | -2,12% |
| Echtzeit USD | - | - | - | - | 50,993$ | -1,06% |
| USA | - | - | - | - | 51,130$ | -0,80% |
| Nasdaq | - | - | - | - | 50,140$ | -2,87% |
| Echtzeit Euro | - | - | - | - | 47,200€ | 2,16% |
| Lang & Schwarz | - | - | - | - | 47,000€ | -1,05% |
| Börse Frankfurt | - | - | - | - | 47,200€ | 2,16% |
Fundamentaldaten der LivaNova PLC Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 1,15 Mrd. | -81,23 Mio. | 17,55 Mio. | 0,32 | - | 145,68 | 2,21 |
| 2022 [USD] | 1,02 Mrd. | -75,14 Mio. | -86,25 Mio. | -1,61 | - | - | 2,47 |
| 2021 [USD] | 1,04 Mrd. | -124,47 Mio. | -135,82 Mio. | -2,68 | - | - | 2,43 |
| 2020 [USD] | 934,24 Mio. | -343,99 Mio. | -343,52 Mio. | -7,13 | - | - | 2,46 |
| 2019 [USD] | 1,08 Mrd. | -185,69 Mio. | -155,18 Mio. | -3,21 | - | - | 2,11 |
| 2018 [USD] | 1,11 Mrd. | -247,45 Mio. | -189,19 Mio. | -3,90 | - | - | 2,06 |
| 2017 [USD] | 1,01 Mrd. | 121,14 Mio. | -25,09 Mio. | -0,52 | - | - | 2,25 |
| 2016 [USD] | 1,21 Mrd. | -33,05 Mio. | -62,79 Mio. | -1,29 | - | - | 1,87 |
| 2015 [USD] | 623,56 Mio. | -58,92 Mio. | -44,42 Mio. | -1,36 | - | - | 3,70 |
| 2014 [USD] | 282,01 Mio. | 79,88 Mio. | 54,89 Mio. | 2,00 | - | 23,60 | 4,48 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der LivaNova PLC Aktie
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.